The monoclonal expansion approach of CRISPR/Cas9-mediated ATF2-KO cells allowed us to abrogate ITH and capture, at least partly, the genetic diversity in the tumor, leading to the identification of a novel regulatory axis between ATF2 and TROP2. The gene discussed is TACSTD2; the disease is neoplasm.